446 related articles for article (PubMed ID: 34407318)
41. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
42. Impact of highly effective CFTR modulator therapy on digital clubbing in patients with cystic fibrosis.
Mahlen T; Barton L; Roberts D
J Cyst Fibros; 2022 Sep; 21(5):861-865. PubMed ID: 35915048
[TBL] [Abstract][Full Text] [Related]
43. The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis.
Costa E; Girotti S; Pauro F; Leufkens HGM; Cipolli M
Orphanet J Rare Dis; 2022 May; 17(1):188. PubMed ID: 35525974
[TBL] [Abstract][Full Text] [Related]
44. Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
Edmondson C; Course CW; Doull I
Arch Dis Child; 2021 Oct; 106(10):941-945. PubMed ID: 33785533
[TBL] [Abstract][Full Text] [Related]
45. To treat or not to treat: CFTR modulators after lung transplantation.
Hayes D; Darland LK; Hjelm MA; Mansour HM; Wikenheiser-Brokamp KA
Pediatr Transplant; 2021 Jun; 25(4):e14007. PubMed ID: 33742748
[TBL] [Abstract][Full Text] [Related]
46. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Rowe SM; Daines C; Ringshausen FC; Kerem E; Wilson J; Tullis E; Nair N; Simard C; Han L; Ingenito EP; McKee C; Lekstrom-Himes J; Davies JC
N Engl J Med; 2017 Nov; 377(21):2024-2035. PubMed ID: 29099333
[TBL] [Abstract][Full Text] [Related]
47. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.
Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M
Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721
[TBL] [Abstract][Full Text] [Related]
48. Survey of patients with cystic fibrosis and caregivers decisions regarding CFTR modulators.
George A; Smith B; Sawicki GS; Goetz DM
Pediatr Pulmonol; 2020 Nov; 55(11):2983-2989. PubMed ID: 32589808
[TBL] [Abstract][Full Text] [Related]
49. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
Schneider EK; Reyes-Ortega F; Li J; Velkov T
Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
[TBL] [Abstract][Full Text] [Related]
50. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
[TBL] [Abstract][Full Text] [Related]
51. Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
Eldredge JA; Oliver MR; Ooi CY
Paediatr Respir Rev; 2024 Jun; 50():54-61. PubMed ID: 38281822
[TBL] [Abstract][Full Text] [Related]
52. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.
Connett GJ
Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974
[TBL] [Abstract][Full Text] [Related]
53. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor.
Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG
Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355
[TBL] [Abstract][Full Text] [Related]
54. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
[TBL] [Abstract][Full Text] [Related]
55. [Therapeutic update in cystic fibrosis].
Durupt S; Nove Josserand R; Durieu I
Rev Med Interne; 2014 Jun; 35(6):388-92. PubMed ID: 24309546
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
57. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
[TBL] [Abstract][Full Text] [Related]
58. Delivering a New Future for People With Cystic Fibrosis.
Burgener EB; Cornfield DN
Pediatrics; 2023 Oct; 152(4):. PubMed ID: 37671451
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
[TBL] [Abstract][Full Text] [Related]
60. [New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein].
Hubert D; Bui S; Marguet C; Colomb-Jung V; Murris-Espin M; Corvol H; Munck A
Rev Mal Respir; 2016 Oct; 33(8):658-665. PubMed ID: 26806675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
